Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis

Ching Feng Cheng, Shu Hui Juan, Jin Jer Chen, Ying Chi Chao, His Hsien Chen, Wei Shiung Lian, Chun Yi Lu, Chung I. Chang, Ted H. Chiu, Heng Lin

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The objective of this study was to evaluate the cardiac toxicity induced by carboplatin, a second generation platinum-containing anti-cancer drug, and to test whether pravastatin can reduce this cardio-toxicity. In the present study, infusion of carboplatin (100 mg/kg) to mice resulted in decreased survival rates and abnormal cardiac histology, concomitant with increased cardiac apoptosis. In addition, treatment of cultured rat cardiomyocytes with carboplatin (100 μM for 48 h) caused marked apoptosis and increased caspase-3, -9, and cytochrome C, but decreased BCL-XL protein expression, and this was inhibited by reactive oxygen species (ROS) scavenger n-acetylcysteine. Furthermore, pretreatment of cardiomyocytes with pravastatin (20 μM) before carboplatin exposure significantly attenuated apoptosis and decreased caspase-3, -9, cytochrome C activity. Lastly, mice pre-treated with pravastatin before carboplatin treatment showed improved survival rate and cardiac function, with reduced cardiomyocyte apoptosis via activating Akt and restoring normal mitochondrial HAX-1 in heart tissue. In summary, our results show that carboplatin can induce cardiotoxicity in vivo and in cultured cells via a mitochondrial pathway related to ROS production, whereas pravastatin administration can reduce such oxidative stress thus prevented cardiac apoptosis. Therefore, pravastatin can be used as a cytoprotective agent prior to carboplatin chemotherapy.

Original languageEnglish
Pages (from-to)883-894
Number of pages12
JournalApoptosis
Volume13
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Pravastatin
Oxidative stress
Carboplatin
Oxidative Stress
Apoptosis
Cardiac Myocytes
Caspase 9
Cytochromes
Caspase 3
Antitumor Drug Screening Assays
Toxicity
Reactive Oxygen Species
Histology
Chemotherapy
Acetylcysteine
Cardiotoxicity
Platinum
Rats
Cultured Cells
Cells

Keywords

  • Apoptosis
  • Carboplatin
  • Cardiomyocytes
  • Cardiotoxicity
  • Reactive oxidative stress
  • Statin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology

Cite this

Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. / Cheng, Ching Feng; Juan, Shu Hui; Chen, Jin Jer; Chao, Ying Chi; Chen, His Hsien; Lian, Wei Shiung; Lu, Chun Yi; Chang, Chung I.; Chiu, Ted H.; Lin, Heng.

In: Apoptosis, Vol. 13, No. 7, 07.2008, p. 883-894.

Research output: Contribution to journalArticle

Cheng, Ching Feng ; Juan, Shu Hui ; Chen, Jin Jer ; Chao, Ying Chi ; Chen, His Hsien ; Lian, Wei Shiung ; Lu, Chun Yi ; Chang, Chung I. ; Chiu, Ted H. ; Lin, Heng. / Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. In: Apoptosis. 2008 ; Vol. 13, No. 7. pp. 883-894.
@article{caa0e055591c44908767e33c94ea2fda,
title = "Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis",
abstract = "The objective of this study was to evaluate the cardiac toxicity induced by carboplatin, a second generation platinum-containing anti-cancer drug, and to test whether pravastatin can reduce this cardio-toxicity. In the present study, infusion of carboplatin (100 mg/kg) to mice resulted in decreased survival rates and abnormal cardiac histology, concomitant with increased cardiac apoptosis. In addition, treatment of cultured rat cardiomyocytes with carboplatin (100 μM for 48 h) caused marked apoptosis and increased caspase-3, -9, and cytochrome C, but decreased BCL-XL protein expression, and this was inhibited by reactive oxygen species (ROS) scavenger n-acetylcysteine. Furthermore, pretreatment of cardiomyocytes with pravastatin (20 μM) before carboplatin exposure significantly attenuated apoptosis and decreased caspase-3, -9, cytochrome C activity. Lastly, mice pre-treated with pravastatin before carboplatin treatment showed improved survival rate and cardiac function, with reduced cardiomyocyte apoptosis via activating Akt and restoring normal mitochondrial HAX-1 in heart tissue. In summary, our results show that carboplatin can induce cardiotoxicity in vivo and in cultured cells via a mitochondrial pathway related to ROS production, whereas pravastatin administration can reduce such oxidative stress thus prevented cardiac apoptosis. Therefore, pravastatin can be used as a cytoprotective agent prior to carboplatin chemotherapy.",
keywords = "Apoptosis, Carboplatin, Cardiomyocytes, Cardiotoxicity, Reactive oxidative stress, Statin",
author = "Cheng, {Ching Feng} and Juan, {Shu Hui} and Chen, {Jin Jer} and Chao, {Ying Chi} and Chen, {His Hsien} and Lian, {Wei Shiung} and Lu, {Chun Yi} and Chang, {Chung I.} and Chiu, {Ted H.} and Heng Lin",
year = "2008",
month = "7",
doi = "10.1007/s10495-008-0214-9",
language = "English",
volume = "13",
pages = "883--894",
journal = "Apoptosis : an international journal on programmed cell death",
issn = "1360-8185",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis

AU - Cheng, Ching Feng

AU - Juan, Shu Hui

AU - Chen, Jin Jer

AU - Chao, Ying Chi

AU - Chen, His Hsien

AU - Lian, Wei Shiung

AU - Lu, Chun Yi

AU - Chang, Chung I.

AU - Chiu, Ted H.

AU - Lin, Heng

PY - 2008/7

Y1 - 2008/7

N2 - The objective of this study was to evaluate the cardiac toxicity induced by carboplatin, a second generation platinum-containing anti-cancer drug, and to test whether pravastatin can reduce this cardio-toxicity. In the present study, infusion of carboplatin (100 mg/kg) to mice resulted in decreased survival rates and abnormal cardiac histology, concomitant with increased cardiac apoptosis. In addition, treatment of cultured rat cardiomyocytes with carboplatin (100 μM for 48 h) caused marked apoptosis and increased caspase-3, -9, and cytochrome C, but decreased BCL-XL protein expression, and this was inhibited by reactive oxygen species (ROS) scavenger n-acetylcysteine. Furthermore, pretreatment of cardiomyocytes with pravastatin (20 μM) before carboplatin exposure significantly attenuated apoptosis and decreased caspase-3, -9, cytochrome C activity. Lastly, mice pre-treated with pravastatin before carboplatin treatment showed improved survival rate and cardiac function, with reduced cardiomyocyte apoptosis via activating Akt and restoring normal mitochondrial HAX-1 in heart tissue. In summary, our results show that carboplatin can induce cardiotoxicity in vivo and in cultured cells via a mitochondrial pathway related to ROS production, whereas pravastatin administration can reduce such oxidative stress thus prevented cardiac apoptosis. Therefore, pravastatin can be used as a cytoprotective agent prior to carboplatin chemotherapy.

AB - The objective of this study was to evaluate the cardiac toxicity induced by carboplatin, a second generation platinum-containing anti-cancer drug, and to test whether pravastatin can reduce this cardio-toxicity. In the present study, infusion of carboplatin (100 mg/kg) to mice resulted in decreased survival rates and abnormal cardiac histology, concomitant with increased cardiac apoptosis. In addition, treatment of cultured rat cardiomyocytes with carboplatin (100 μM for 48 h) caused marked apoptosis and increased caspase-3, -9, and cytochrome C, but decreased BCL-XL protein expression, and this was inhibited by reactive oxygen species (ROS) scavenger n-acetylcysteine. Furthermore, pretreatment of cardiomyocytes with pravastatin (20 μM) before carboplatin exposure significantly attenuated apoptosis and decreased caspase-3, -9, cytochrome C activity. Lastly, mice pre-treated with pravastatin before carboplatin treatment showed improved survival rate and cardiac function, with reduced cardiomyocyte apoptosis via activating Akt and restoring normal mitochondrial HAX-1 in heart tissue. In summary, our results show that carboplatin can induce cardiotoxicity in vivo and in cultured cells via a mitochondrial pathway related to ROS production, whereas pravastatin administration can reduce such oxidative stress thus prevented cardiac apoptosis. Therefore, pravastatin can be used as a cytoprotective agent prior to carboplatin chemotherapy.

KW - Apoptosis

KW - Carboplatin

KW - Cardiomyocytes

KW - Cardiotoxicity

KW - Reactive oxidative stress

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=46549083150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46549083150&partnerID=8YFLogxK

U2 - 10.1007/s10495-008-0214-9

DO - 10.1007/s10495-008-0214-9

M3 - Article

C2 - 18483861

AN - SCOPUS:46549083150

VL - 13

SP - 883

EP - 894

JO - Apoptosis : an international journal on programmed cell death

JF - Apoptosis : an international journal on programmed cell death

SN - 1360-8185

IS - 7

ER -